Cargando…
Long‐term open‐label perampanel: Generalized tonic–clonic seizures in idiopathic generalized epilepsy
OBJECTIVE: Assess the longer‐term efficacy and safety of adjunctive perampanel (up to 12 mg/day) in patients aged ≥12 years with generalized tonic–clonic (GTC) seizures from the Open‐label Extension (OLEx) Phase of Study 332 to determine whether responses obtained during the Core Study are maintaine...
Autores principales: | French, Jacqueline A., Wechsler, Robert T., Trinka, Eugen, Brandt, Christian, O'Brien, Terence J., Patten, Anna, Salah, Alejandro, Malhotra, Manoj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436298/ https://www.ncbi.nlm.nih.gov/pubmed/35445567 http://dx.doi.org/10.1002/epi4.12602 |
Ejemplares similares
-
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
por: French, Jacqueline A., et al.
Publicado: (2015) -
Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures
por: Besag, Frank MC, et al.
Publicado: (2016) -
Time to exceed pre‐randomization monthly seizure count for perampanel in participants with primary generalized tonic–clonic seizures: A potential clinical end point
por: Kerr, Wesley T., et al.
Publicado: (2022) -
Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020) -
Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)